DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Nebulized Ceftazidime and Amikacin in Ventilator Associated Pneumonia

Information source: Groupe Hospitalier Pitie-Salpetriere
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Pneumonia

Intervention: ceftazidime and amikacin (Drug); ceftazidime and amikacin (Drug)

Phase: Phase 2

Status: Completed

Sponsored by: Groupe Hospitalier Pitie-Salpetriere

Official(s) and/or principal investigator(s):
Jean-Jacques Rouby, MD, PhD, Principal Investigator, Affiliation: La Pitie-Salpetriere hospital


Pseudomonas aeruginosa is one of the major causative microorganisms of ventilator-associated pneumonia often resistant to antibiotics. In experimental models, nebulization of antibiotics delivers high lung tissue concentrations of antibiotics in infected lungs and increases lung bacterial killing. The aim of the study is to assess the efficiency of nebulized ceftazidime and amikacin in the treatment of pneumonia caused by Pseudomonas aeruginosa in ventilated patients.

Clinical Details

Official title: Assessment of Efficiency of Nebulized Ceftazidime and Amikacin in Treatment of Ventilator Associated Pneumonia Caused by Pseudomonas Aeruginosa

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Bacterial killing

Secondary outcome: Changes of lung aeration


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Male or female >18 years old, ventilator associated pneumonia caused by pseudomonas


- Written informed consent provided by the relatives

Exclusion Criteria:

- Pseudomonas aeruginosa resistant to ceftazidime and amikacin

- Pseudomonas aeruginosa pneumonia associated with other infections requiring

intravenous treatment

- Severe septic shock and severe hypoxemia

- Allergy to ceftazidime or amikacin

Locations and Contacts

Intensive care unit, Department of anesthesiology, La pitie-Salpetriere hospital, Paris 75013, France
Additional Information

Starting date: October 2004
Last updated: November 5, 2008

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017